A59L (p.Ala59Leu) variant of KRAS (GTPase KRas)
A59L (p.Ala59Leu) in KRAS (GTPase KRas) is a missense change. Clinical records from ClinVar, EBI, and UniProt describe it as likely pathogenic in the context of Cardiofaciocutaneous syndrome 2. The available variant effect predictions contribute to a CATVariant prioritization score of 1.00 / 1. The record also includes experimental measurements, published literature, and structural context.
A59L (p.Ala59Leu) variant details
- p.Ala59Leu
- rs2548920539
- ClinGen CA2580085354
- ClinVar RCV003140510
- Likely pathogenic
- Cardiofaciocutaneous syndrome 2
- Missense
- Variant Prioritization Score for Impact Estimate 0.997
- ESM-1b 1.00
- AlphaMissense 0.99
- ClinVar: Likely pathogenic (Cardiofaciocutaneous syndrome 2)
- EBI: Likely pathogenic (in GASC)
- UniProt: Likely pathogenic (in GASC)
- Structural context available
- KRAS activity — DMSO (standardized): score 0.655
- Cited in: Cardiofaciocutaneous Syndrome. (PMID 20301365)